CA2334577A1 - Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors - Google Patents
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors Download PDFInfo
- Publication number
- CA2334577A1 CA2334577A1 CA002334577A CA2334577A CA2334577A1 CA 2334577 A1 CA2334577 A1 CA 2334577A1 CA 002334577 A CA002334577 A CA 002334577A CA 2334577 A CA2334577 A CA 2334577A CA 2334577 A1 CA2334577 A1 CA 2334577A1
- Authority
- CA
- Canada
- Prior art keywords
- estrogen receptor
- selective estrogen
- sex steroid
- combination
- receptor modulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002243 precursor Substances 0.000 title abstract 4
- 239000003163 gonadal steroid hormone Substances 0.000 title abstract 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title abstract 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 title abstract 3
- 208000001132 Osteoporosis Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- QADHLRWLCPCEKT-UHFFFAOYSA-N 5-androstenediol Chemical compound C1C(O)CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC=C21 QADHLRWLCPCEKT-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960002847 prasterone Drugs 0.000 abstract 1
- 229950009829 prasterone sulfate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having general structure (I) and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3.beta.,17.beta.-diol and compounds converted in vivo to one of the foregoing precursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2632567A CA2632567C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/096,284 | 1998-06-11 | ||
US09/096,284 US6465445B1 (en) | 1998-06-11 | 1998-06-11 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
PCT/CA1999/000538 WO1999063974A2 (en) | 1998-06-11 | 1999-06-10 | Selective estrogen receptor modulator in combination with denydroepiandrosterone (dhea) or analogues |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2632567A Division CA2632567C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2334577A1 true CA2334577A1 (en) | 1999-12-16 |
CA2334577C CA2334577C (en) | 2008-08-05 |
Family
ID=22256661
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2632567A Expired - Lifetime CA2632567C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768828A Expired - Lifetime CA2768828C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768841A Expired - Lifetime CA2768841C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768773A Expired - Lifetime CA2768773C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA002334577A Expired - Lifetime CA2334577C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768682A Expired - Lifetime CA2768682C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768882A Expired - Lifetime CA2768882C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2632567A Expired - Lifetime CA2632567C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768828A Expired - Lifetime CA2768828C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768841A Expired - Lifetime CA2768841C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768773A Expired - Lifetime CA2768773C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2768682A Expired - Lifetime CA2768682C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CA2768882A Expired - Lifetime CA2768882C (en) | 1998-06-11 | 1999-06-10 | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
Country Status (29)
Country | Link |
---|---|
US (6) | US6465445B1 (en) |
EP (5) | EP2386304B9 (en) |
JP (3) | JP2002517433A (en) |
KR (6) | KR100944261B1 (en) |
CN (2) | CN1240388C (en) |
AR (1) | AR043075A1 (en) |
AT (1) | ATE308326T1 (en) |
AU (1) | AU4253099A (en) |
BR (1) | BR9911116A (en) |
CA (7) | CA2632567C (en) |
CY (4) | CY1113712T1 (en) |
DE (1) | DE69928104T2 (en) |
DK (5) | DK1623712T3 (en) |
ES (5) | ES2253922T3 (en) |
HK (1) | HK1040367B (en) |
HU (2) | HU230495B1 (en) |
ID (1) | ID28696A (en) |
IL (3) | IL140178A0 (en) |
MX (1) | MXPA00012306A (en) |
MY (3) | MY151187A (en) |
NO (2) | NO331022B1 (en) |
NZ (1) | NZ508801A (en) |
PL (4) | PL203343B1 (en) |
PT (4) | PT2386305E (en) |
RU (1) | RU2246947C2 (en) |
TR (5) | TR200103455T2 (en) |
TW (2) | TWI371279B (en) |
WO (1) | WO1999063974A2 (en) |
ZA (1) | ZA200007297B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021323A1 (en) * | 2007-08-10 | 2009-02-19 | Endorecherche, Inc. | Dhea compositions for treating menopause |
WO2011156908A1 (en) * | 2010-06-16 | 2011-12-22 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
WO2015135061A1 (en) * | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012623A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) * | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CN1146554C (en) * | 1998-08-14 | 2004-04-21 | 先灵公司 | Enantioselective synthesis |
US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
AU2156800A (en) * | 1998-12-18 | 2000-07-12 | Schering Corporation | Oral antiestrogen pharmaceutical composition |
EP1189619A4 (en) | 1999-06-11 | 2004-06-09 | Watson Pharmaceuticals Inc | Administration of non-oral androgenic steroids to women |
TR200403328T2 (en) | 1999-07-06 | 2005-03-21 | Endorecherche, Inc. | Methods of treatment and / or prevention of weight gain. |
AU7896100A (en) * | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
SK9592002A3 (en) * | 2000-01-28 | 2003-12-02 | Endorech Inc | A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit |
AU2001241779A1 (en) | 2000-02-25 | 2001-09-03 | Hollis-Eden Pharmaceuticals, Inc. | Method of treatment of prostate cancer |
EP1282615B1 (en) * | 2000-03-01 | 2011-10-19 | N.V. Organon | Chroman derivatives as estrogenic compounds |
MXPA02012897A (en) * | 2000-07-06 | 2003-10-24 | Wyeth Corp | Combinations of bisphosphonates, estrogenic agents and optionally estrogens. |
EP1296674A2 (en) * | 2000-07-06 | 2003-04-02 | Wyeth | Use of substituted indole compounds for increasing nitric oxide synthase activity |
WO2002003988A2 (en) * | 2000-07-06 | 2002-01-17 | Wyeth | Use of substituted indole compounds for treating neuropeptide y-related conditions |
DK1318837T3 (en) | 2000-08-11 | 2005-01-10 | Wyeth Corp | Method of treating estrogen receptor positive carcinoma |
EP1192945A3 (en) * | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
IL145876A0 (en) * | 2000-10-17 | 2002-07-25 | Pfizer Prod Inc | Methods and kits for improving vascular health |
AU781168B2 (en) * | 2001-01-26 | 2005-05-12 | Pfizer Products Inc. | Method of treating certain cancers using an estrogen agonist/antagonist |
FR2827764B1 (en) * | 2001-07-27 | 2005-08-19 | Oreal | COMPOSITION, IN PARTICULAR COSMETIC, CONTAINING A STEROID AND A GLYCOL |
CA2448235A1 (en) | 2001-07-31 | 2003-02-13 | Pfizer Products Inc. | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins |
US20040044226A1 (en) * | 2001-10-15 | 2004-03-04 | Dininno Frank P. | Estrogen receptor modulators |
WO2003091239A1 (en) * | 2002-04-24 | 2003-11-06 | Merck & Co., Inc. | Estrogen receptor modulators |
US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
EP1658036A2 (en) * | 2003-08-26 | 2006-05-24 | Board of Regents of the University of Texas System | Estrogen receptor modulators and uses thereof |
NZ553834A (en) | 2004-09-21 | 2010-03-26 | Novogen Res Pty Ltd | 7-hydroxy-3,4-diphenyl-chroman and chromene derivatives |
US8080675B2 (en) | 2004-09-21 | 2011-12-20 | Marshall Edwards, Inc. | Chroman derivatives, medicaments and use in therapy |
US8941594B2 (en) * | 2004-10-01 | 2015-01-27 | Nvidia Corporation | Interface, circuit and method for interfacing with an electronic device |
ES2326387T3 (en) | 2005-03-24 | 2009-10-08 | Nolabs Ab | COSMETIC TREATMENT WITH NITRIC OXIDE, DEVICE FOR CARRYING OUT SUCH TREATMENT AND MANUFACTURING PROCEDURE OF THE SAME. |
AU2007252991B2 (en) | 2006-05-22 | 2012-08-02 | Hormos Medical Ltd. | Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis |
BRPI0711525A2 (en) | 2006-06-02 | 2011-11-01 | Pear Tree Women S Health Care | Pharmaceutical composition and method for treating symptoms of atrophic vaginitis |
EP2121553B1 (en) | 2007-02-14 | 2012-06-27 | Hormos Medical Ltd. | Method for the preparation of therapeutically valuable triphenylbutene derivatives |
US7504530B2 (en) | 2007-02-14 | 2009-03-17 | Hormos Medical Ltd. | Methods for the preparation of fispemifene from ospemifene |
AU2012204083C1 (en) * | 2007-08-10 | 2015-02-05 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US20100075937A1 (en) * | 2008-09-24 | 2010-03-25 | Hollis-Eden Pharmaceuticals, Inc. | Patient populations and treatment methods |
EP3023433A1 (en) | 2009-02-05 | 2016-05-25 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
US20120142645A1 (en) * | 2009-03-17 | 2012-06-07 | Marx Christine E | Neuroactive steroid compositions and methods of use for lowering cholesterol |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
AU2014201406B2 (en) * | 2009-06-16 | 2016-08-11 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
PL2580210T3 (en) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
EP2635273B1 (en) | 2010-11-01 | 2020-01-08 | MEI Pharma, Inc. | Isoflavonoid compositions and methods for the treatment of cancer |
WO2013006608A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Topical compositions |
WO2013006613A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for same |
ES2545337T3 (en) * | 2011-07-19 | 2015-09-10 | Pantarhei Bioscience B.V. | Tablet containing dehydroepiandrosterone (DHEA) |
US9320744B2 (en) | 2011-10-19 | 2016-04-26 | Dhea Llc | DHEA bioadhesive controlled release gel |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (en) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
AU2012353660A1 (en) | 2011-12-16 | 2014-06-12 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
CN102631677A (en) * | 2012-04-19 | 2012-08-15 | 中国农业大学 | Pharmaceutical composition for preventing and/or treating atherosclerosis |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
EP2909164A1 (en) | 2012-10-19 | 2015-08-26 | Fermion Oy | A process for the preparation of ospemifene |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
US9884067B2 (en) | 2013-03-14 | 2018-02-06 | University Of Maryland, Baltimore | Androgen receptor down-regulating agents and uses thereof |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
WO2015021382A2 (en) | 2013-08-08 | 2015-02-12 | Novan, Inc. | Topical compositions and methods of using the same |
US10206947B2 (en) | 2013-08-08 | 2019-02-19 | Novan, Inc. | Topical compositions and methods of using the same |
WO2015023710A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
AR100562A1 (en) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY |
ES2807200T3 (en) | 2014-07-11 | 2021-02-22 | Novan Inc | Topical antiviral compositions and procedures for their use |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
WO2016018993A1 (en) | 2014-07-29 | 2016-02-04 | Therapeuticsmd, Inc. | Transdermal cream |
GB201416186D0 (en) * | 2014-09-12 | 2014-10-29 | Redx Pharma Ltd | Compounds |
US10980774B2 (en) | 2015-02-02 | 2021-04-20 | Mei Pharma, Inc. | Combination therapies |
US10452661B2 (en) * | 2015-06-18 | 2019-10-22 | Microsoft Technology Licensing, Llc | Automated database schema annotation |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR102319497B1 (en) | 2016-03-02 | 2021-11-01 | 노반, 인크. | Composition for treating inflammation and method for treating inflammation |
CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
CN109310630A (en) | 2016-04-13 | 2019-02-05 | 诺万公司 | For treating composition, system, kit and the method for infection |
FR3052805B1 (en) | 2016-06-20 | 2020-06-26 | Safran Aircraft Engines | IMPROVED MONOBLOCK BLADE DISC, ROTATING PART OF A TURBOMACHINE COMPRISING SUCH A DISC AND ASSOCIATED TURBOMACHINE |
CN109224029A (en) * | 2018-09-30 | 2019-01-18 | 泓博元生命科技(深圳)有限公司 | Blood-fat reducing composition, preparation containing NMN and the preparation method and application thereof |
US20220305030A1 (en) * | 2019-10-03 | 2022-09-29 | Caren Pharmaceuticals, Inc. | Combination hormone formulations and therapies |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
BR112023001557A2 (en) | 2020-07-28 | 2023-04-04 | Jazz Pharmaceuticals Ireland Ltd | CAST BICYCLIC RAF INHIBITORS AND METHODS FOR THE USE THEREOF |
WO2023156803A1 (en) * | 2022-02-17 | 2023-08-24 | Debreceni Egyetem | Dhea-derived steroids |
CN115554403B (en) * | 2022-08-16 | 2024-03-08 | 山东大学 | Use of the steroid hormone DHEA as receptor ADGRG2 agonist ligand |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US536220A (en) * | 1895-03-26 | Puzzle | ||
US550107A (en) * | 1895-11-19 | Thirds to henry zervas and julius wegert | ||
DK122125B (en) | 1967-10-04 | 1972-01-24 | Schering Ag | Analogous process for the preparation of therapeutically active carboxylic acid esters of 3β-hydroxy-5-androstan-17-one (dehydroepiandrosterone) having 7-11 carbon atoms in the ester residue. |
US3797494A (en) | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3797444A (en) | 1971-04-19 | 1974-03-19 | H Stubbs | Towing guide |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US4005200A (en) * | 1975-07-17 | 1977-01-25 | Kanebo, Ltd. | Method for improving the maturity of the parturient canal and the sensitivity to oxytocin |
US4542129A (en) | 1982-08-16 | 1985-09-17 | Norman Orentreich | DHEA Formulations and methods for treating dry skin |
US4496556A (en) | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
DE3333240A1 (en) | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS |
US4725439A (en) | 1984-06-29 | 1988-02-16 | Alza Corporation | Transdermal drug delivery device |
JPH0680016B2 (en) | 1984-08-02 | 1994-10-12 | ラブリ−,フエルナンド | Pharmaceutical composition for combined treatment of hormone-dependent cancer |
US4624665A (en) | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4666441A (en) | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
IE60941B1 (en) | 1986-07-10 | 1994-09-07 | Elan Transdermal Ltd | Transdermal drug delivery device |
US4816258A (en) | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
JP2551590B2 (en) * | 1987-06-26 | 1996-11-06 | 株式会社リコー | Speed control method for copier optical system |
JPS6440428A (en) | 1987-08-07 | 1989-02-10 | Daiichi Yakuhin Sangyo Kk | Antihyperlipemia |
US5064654A (en) | 1989-01-11 | 1991-11-12 | Ciba-Geigy Corporation | Mixed solvent mutually enhanced transdermal therapeutic system |
US5162037A (en) | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
HU208150B (en) | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
US5686465A (en) | 1988-10-31 | 1997-11-11 | Endorecherche Inc. | Sex steroid activity inhibitors |
US5393785A (en) | 1988-10-31 | 1995-02-28 | Endorecherche, Inc. | Therapeutic antiestrogens |
US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
CA2004203A1 (en) | 1988-12-01 | 1990-06-01 | Sharad K. Govil | Compositions for transdermal delivery of estradiol |
US4920115A (en) * | 1988-12-28 | 1990-04-24 | Virginia Commonwealth University | Method of lowering LDL cholesterol in blood |
ZA901847B (en) | 1989-03-10 | 1991-10-30 | Endorecherche Inc | Combination therapy for the treatment of estrogen sensitive diseases |
US5071644A (en) | 1990-08-07 | 1991-12-10 | Mediventures, Inc. | Topical drug delivery with thermo-irreversible gels |
ZA924811B (en) | 1991-06-28 | 1993-12-29 | Endorecherche Inc | Controlled release systems and low dose androgens |
HU222501B1 (en) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | Controlled release pharmaceutical composition containing mpa or mga and process for its preparation |
US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
HUT64815A (en) | 1992-09-04 | 1994-03-28 | Berki | An external correcting and fixing apparatus for treatment of fractures and defomities of bones as well as correcting unit preferably for external correcting and fixing units |
US5354861A (en) | 1992-11-04 | 1994-10-11 | National University Of Singapore | 2-(benzyl)-3-arylbenzofurans as antitumour and hypocholesterolemic agents |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
US5776923A (en) | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
EP0680327B1 (en) * | 1993-01-19 | 2004-09-15 | Endorecherche Inc. | Therapeutic uses and delivery systems of dehydroepiandrosterone |
DE4401554A1 (en) | 1993-02-16 | 1994-08-18 | Freund Andreas | Product for the therapy and prophylaxis of disorders occurring in plasma lipid inbalance |
DE69405491T2 (en) | 1993-06-24 | 1998-02-19 | Lilly Co Eli | Anti-estrogens 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents |
US5418252A (en) | 1993-10-15 | 1995-05-23 | Eli Lilly And Company | Method for inhibiting cartilage degradation |
US5441964A (en) | 1993-10-15 | 1995-08-15 | Eli Lilly And Company | Methods for inhibiting bone loss using substituted benzothiophene |
US5391557A (en) | 1993-10-15 | 1995-02-21 | Eli Lilly And Company | Methods for the treatment of peri-menopausal syndrome |
US5482950A (en) | 1993-10-15 | 1996-01-09 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5446061A (en) * | 1993-11-05 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
ATE215826T1 (en) * | 1993-11-19 | 2002-04-15 | Jenapharm Gmbh | CARCINOSTATIC AGENT FOR HORMONE THERAPY CONTAINING DIENOGEST AS AN ACTIVE INGREDIENT |
US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
US5591753A (en) | 1994-01-28 | 1997-01-07 | Eli Lilly And Company | Combination treatment for osteoporosis |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
US5425429A (en) * | 1994-06-16 | 1995-06-20 | Thompson; Michael C. | Method and apparatus for forming lateral boreholes |
US5681308A (en) | 1994-06-24 | 1997-10-28 | Stuart D. Edwards | Ablation apparatus for cardiac chambers |
ZA956029B (en) | 1994-07-22 | 1997-01-20 | Lilly Co Eli | Combination treatment for inhibiting bone loss |
HUT76890A (en) | 1994-08-22 | 1997-12-29 | Lilly Co Eli | Use of benzotiophene derivatives for producing phamaceutical compositions against endometrial cancer |
EP0769946A4 (en) | 1994-08-22 | 1997-11-05 | Lilly Co Eli | Methods of maintaining teeth and oral bone |
US5502074A (en) | 1994-08-22 | 1996-03-26 | Eli Lilly And Company | Benzothiophenes for bone healing and fracture repair |
US5550123A (en) | 1994-08-22 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone prosthesis degeneration |
GB9418067D0 (en) | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
US5484798A (en) | 1994-09-20 | 1996-01-16 | Eli Lilly And Company | Benzothiopene compounds, compositions, and method of inhibiting restenosis |
US6703407B1 (en) | 1994-09-20 | 2004-03-09 | Eli Lilly And Company | Benzofuran compounds, compositions, and methods |
US5637598A (en) | 1994-11-18 | 1997-06-10 | Eli Lilly And Company | Methods of inhibiting bone loss |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
AU707290B2 (en) | 1994-11-29 | 1999-07-08 | Hoechst Marion Roussel, Inc. | Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis |
CN1168098A (en) * | 1995-01-13 | 1997-12-17 | 诺沃挪第克公司 | Use of 3,4-diphenyl chromans for manufacture of pharmaceutical composition for treatment or prophylaxis of hyperlipopropteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia...... |
US5489587A (en) | 1995-01-20 | 1996-02-06 | Eli Lilly And Company | Benzofurans used to inhibit bone loss |
US5571808A (en) | 1995-01-31 | 1996-11-05 | Eli Lilly And Company | Method for treating smoking-related bone loss |
US5552401A (en) | 1995-02-28 | 1996-09-03 | Eli Lilly And Company | 2-benzyl-3-arylbenzothiophenes |
US5523309A (en) | 1995-03-10 | 1996-06-04 | Eli Lilly And Company | Benzofuran pharmaceutical compounds |
US5567828A (en) | 1995-06-07 | 1996-10-22 | Eli Lilly And Company | Compounds and compositions with nitrogen-containing non-basic side |
DE69600709T2 (en) | 1995-06-07 | 1999-03-18 | Lilly Co Eli | Side chain compounds with N-acylated piperidine and compositions |
US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
AU1367197A (en) | 1996-01-11 | 1997-08-01 | Novo Nordisk A/S | Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer |
US5747059A (en) | 1996-01-11 | 1998-05-05 | Novo Nordisk A/S | Atrophy of skin/mucous membrane |
CZ217298A3 (en) | 1996-01-11 | 1999-01-13 | Novo Nordisk A/S | Application of 3,4-diphenyl chromates for preparing pharmaceutical preparation |
US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
ES2178750T3 (en) * | 1996-02-14 | 2003-01-01 | Aventis Pharma Inc | 17-BETA- ICLOPROPIL (AMINO / OXI) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF 5-ALFA-REDUCTASE AND C17-20-LIASA DE TESTOSTERONA. |
US6432982B1 (en) | 1996-02-21 | 2002-08-13 | Eli Lilly And Company | Benzothiophenes, and formulations and methods using same |
NZ331461A (en) | 1996-02-22 | 1999-05-28 | Lilly Co Eli | Benzothiophenes, formulations containing same, and methods |
IL120262A (en) | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
WO1997032837A1 (en) | 1996-03-06 | 1997-09-12 | Sumitomo Pharmaceuticals Co., Ltd. | Nonsteroidal estrogen derivatives |
EP0801066A1 (en) | 1996-03-12 | 1997-10-15 | Eli Lilly And Company | Heterocyclic substituted benzothiophenes and pharmaceutical compositions |
DE60308917T2 (en) * | 1996-04-11 | 2006-12-28 | Loria, Roger | Use of a composition containing 5-androstene-3β, 17α-diol |
DE122009000061I1 (en) | 1996-04-19 | 2009-12-31 | Wyeth N D Ges D Staates Delawa | Estrogenic compounds |
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5843984A (en) | 1996-05-09 | 1998-12-01 | Eli Lilly And Company | Sulfated benzothiophene derivatives, methods of use and formulations containing same |
GB9616700D0 (en) * | 1996-08-09 | 1996-09-25 | Carey Beverly J | Hormone supplement |
JP2002514174A (en) * | 1996-08-28 | 2002-05-14 | イーライ・リリー・アンド・カンパニー | Amorphous benzothiophenes, production and use |
US6511970B1 (en) * | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
US5855920A (en) * | 1996-12-13 | 1999-01-05 | Chein; Edmund Y. M. | Total hormone replacement therapy |
US5861391A (en) * | 1997-01-29 | 1999-01-19 | Research Development Foundation | Use of dehydroepiandrosterone to treat primary adrenal insufficiency and Addison's disease |
BR9807828A (en) * | 1997-02-07 | 2000-03-08 | Theratech Inc | Compositions and method for testosterone supplementation in women with symptoms of testosterone deficiency |
GB9708716D0 (en) * | 1997-04-29 | 1997-06-18 | Imperial College | Chronic heart failure |
UA53716C2 (en) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | A substituted dipeptide tartaric salt as an agent stimulating the growth hormone secretion |
CO4940467A1 (en) * | 1997-06-27 | 2000-07-24 | Smithkline Beecham Corp | NEW METHODS |
US5908859A (en) * | 1997-08-11 | 1999-06-01 | Eli Lilly And Company | Benzothiophenes for inhibiting hyperlipidemia |
AU740758B2 (en) * | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
DK1076558T3 (en) | 1998-05-15 | 2003-11-03 | Wyeth Corp | 2-Phenyl-1- [4- (2-aminoethoxy) benzyl] indole in combination with estrogens |
MXPA00012304A (en) * | 1998-06-11 | 2003-05-15 | Endorech Inc | PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3beta,17beta-DIOL. |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
US7005428B1 (en) * | 1998-06-11 | 2006-02-28 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
HUP9900284A2 (en) | 1999-02-09 | 2001-02-28 | János Váradi | Three phase hydraulic spring element for road and railway vehicles |
TR200403328T2 (en) * | 1999-07-06 | 2005-03-21 | Endorecherche, Inc. | Methods of treatment and / or prevention of weight gain. |
AU7896100A (en) * | 1999-10-14 | 2001-04-23 | Endorecherche Inc. | Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance |
CN101106999B (en) * | 2004-10-20 | 2017-06-09 | 恩多研究公司 | Single sex steroid precursor is used to prevent and treat the colpoxerosis and sex dysfunction of postmenopausal women |
US8268806B2 (en) * | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
-
1998
- 1998-06-11 US US09/096,284 patent/US6465445B1/en not_active Expired - Lifetime
-
1999
- 1999-06-10 CA CA2632567A patent/CA2632567C/en not_active Expired - Lifetime
- 1999-06-10 ES ES99955419T patent/ES2253922T3/en not_active Expired - Lifetime
- 1999-06-10 AT AT99955419T patent/ATE308326T1/en active
- 1999-06-10 PL PL380786A patent/PL203343B1/en unknown
- 1999-06-10 PL PL345887A patent/PL199798B1/en unknown
- 1999-06-10 NZ NZ508801A patent/NZ508801A/en not_active IP Right Cessation
- 1999-06-10 CA CA2768828A patent/CA2768828C/en not_active Expired - Lifetime
- 1999-06-10 TR TR2001/03455T patent/TR200103455T2/en unknown
- 1999-06-10 CN CNB998095729A patent/CN1240388C/en not_active Expired - Fee Related
- 1999-06-10 PL PL99379648A patent/PL195772B1/en unknown
- 1999-06-10 CA CA2768841A patent/CA2768841C/en not_active Expired - Lifetime
- 1999-06-10 CA CA2768773A patent/CA2768773C/en not_active Expired - Lifetime
- 1999-06-10 AR ARP990102785A patent/AR043075A1/en not_active Application Discontinuation
- 1999-06-10 DK DK05018115.5T patent/DK1623712T3/en active
- 1999-06-10 KR KR1020007014056A patent/KR100944261B1/en not_active IP Right Cessation
- 1999-06-10 JP JP2000553043A patent/JP2002517433A/en not_active Withdrawn
- 1999-06-10 EP EP11174925.5A patent/EP2386304B9/en not_active Expired - Lifetime
- 1999-06-10 TR TR2001/00551T patent/TR200100551T2/en unknown
- 1999-06-10 BR BR9911116-0A patent/BR9911116A/en not_active Application Discontinuation
- 1999-06-10 TR TR2001/03456T patent/TR200103456T2/en unknown
- 1999-06-10 CA CA002334577A patent/CA2334577C/en not_active Expired - Lifetime
- 1999-06-10 KR KR1020097001802A patent/KR20090018870A/en not_active Application Discontinuation
- 1999-06-10 DK DK11174930.5T patent/DK2399582T3/en active
- 1999-06-10 PT PT111749339T patent/PT2386305E/en unknown
- 1999-06-10 DK DK11174925.5T patent/DK2386304T3/en active
- 1999-06-10 RU RU2001101487/15A patent/RU2246947C2/en not_active IP Right Cessation
- 1999-06-10 DE DE69928104T patent/DE69928104T2/en not_active Expired - Lifetime
- 1999-06-10 TR TR2001/03454T patent/TR200103454T2/en unknown
- 1999-06-10 EP EP11174933.9A patent/EP2386305B9/en not_active Expired - Lifetime
- 1999-06-10 DK DK99955419T patent/DK1083905T3/en active
- 1999-06-10 CA CA2768682A patent/CA2768682C/en not_active Expired - Lifetime
- 1999-06-10 PT PT111749305T patent/PT2399582E/en unknown
- 1999-06-10 HU HU0103345A patent/HU230495B1/en not_active IP Right Cessation
- 1999-06-10 PL PL380789A patent/PL203704B1/en unknown
- 1999-06-10 ES ES11174925.5T patent/ES2463868T3/en not_active Expired - Lifetime
- 1999-06-10 EP EP11174930.5A patent/EP2399582B9/en not_active Expired - Lifetime
- 1999-06-10 EP EP05018115A patent/EP1623712B1/en not_active Expired - Lifetime
- 1999-06-10 WO PCT/CA1999/000538 patent/WO1999063974A2/en active Application Filing
- 1999-06-10 KR KR1020097001806A patent/KR20090016771A/en not_active Application Discontinuation
- 1999-06-10 ES ES05018115T patent/ES2399051T3/en not_active Expired - Lifetime
- 1999-06-10 PT PT50181155T patent/PT1623712E/en unknown
- 1999-06-10 AU AU42530/99A patent/AU4253099A/en not_active Abandoned
- 1999-06-10 ES ES11174933.9T patent/ES2458218T3/en not_active Expired - Lifetime
- 1999-06-10 KR KR1020097001803A patent/KR20090018226A/en not_active Application Discontinuation
- 1999-06-10 PT PT111749255T patent/PT2386304E/en unknown
- 1999-06-10 KR KR1020097001805A patent/KR20090018871A/en not_active Application Discontinuation
- 1999-06-10 KR KR1020097001804A patent/KR20090018227A/en not_active Application Discontinuation
- 1999-06-10 DK DK11174933.9T patent/DK2386305T3/en active
- 1999-06-10 EP EP99955419A patent/EP1083905B1/en not_active Expired - Lifetime
- 1999-06-10 ES ES11174930.5T patent/ES2473040T3/en not_active Expired - Lifetime
- 1999-06-10 CA CA2768882A patent/CA2768882C/en not_active Expired - Lifetime
- 1999-06-10 IL IL14017899A patent/IL140178A0/en unknown
- 1999-06-10 TR TR2001/03453T patent/TR200103453T2/en unknown
- 1999-06-10 ID IDW20010032A patent/ID28696A/en unknown
- 1999-06-10 CN CNA2004100974664A patent/CN1636566A/en active Pending
- 1999-06-10 MX MXPA00012306A patent/MXPA00012306A/en active IP Right Grant
- 1999-06-11 US US09/330,799 patent/US6670346B1/en not_active Expired - Lifetime
- 1999-06-11 MY MYPI1101365 patent/MY151187A/en unknown
- 1999-06-11 TW TW096131870A patent/TWI371279B/en not_active IP Right Cessation
- 1999-06-11 TW TW088109824A patent/TWI258369B/en not_active IP Right Cessation
- 1999-06-11 MY MYPI99002409A patent/MY125047A/en unknown
- 1999-06-11 MY MYPI20053216A patent/MY157030A/en unknown
-
2000
- 2000-12-07 IL IL140178A patent/IL140178A/en not_active IP Right Cessation
- 2000-12-08 NO NO20006254A patent/NO331022B1/en not_active IP Right Cessation
- 2000-12-08 ZA ZA200007297A patent/ZA200007297B/en unknown
-
2002
- 2002-02-28 HU HUP1600307 patent/HU1600307D0/en unknown
- 2002-03-07 HK HK02101755.1A patent/HK1040367B/en not_active IP Right Cessation
-
2003
- 2003-12-30 US US10/749,981 patent/US7429576B2/en not_active Expired - Fee Related
-
2006
- 2006-10-03 US US11/542,733 patent/US8188066B2/en not_active Expired - Fee Related
- 2006-10-03 US US11/542,789 patent/US7943603B2/en not_active Expired - Fee Related
- 2006-10-03 US US11/542,788 patent/US7884092B2/en not_active Expired - Fee Related
-
2007
- 2007-03-05 JP JP2007054169A patent/JP2007191484A/en active Pending
- 2007-08-07 IL IL185087A patent/IL185087A0/en unknown
-
2009
- 2009-07-20 NO NO20092730A patent/NO332187B1/en not_active IP Right Cessation
-
2012
- 2012-11-12 JP JP2012248384A patent/JP2013049703A/en active Pending
-
2013
- 2013-02-21 CY CY20131100161T patent/CY1113712T1/en unknown
-
2014
- 2014-05-09 CY CY20141100331T patent/CY1115069T1/en unknown
- 2014-06-06 CY CY20141100406T patent/CY1115231T1/en unknown
- 2014-06-23 CY CY20141100459T patent/CY1115317T1/en unknown
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8835413B2 (en) | 2004-10-20 | 2014-09-16 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
US10478443B2 (en) | 2004-10-20 | 2019-11-19 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of sexual dysfunction in postmenopausal women |
US10076525B2 (en) | 2004-10-20 | 2018-09-18 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with selective estrogen receptor modulators for the prevention and treatment of dyspareunia in postmenopausal women |
CN109893526A (en) * | 2007-08-10 | 2019-06-18 | 恩多研究公司 | The DEHA composition for treating menopause |
US8268806B2 (en) | 2007-08-10 | 2012-09-18 | Endorecherche, Inc. | Pharmaceutical compositions |
AU2008286651B2 (en) * | 2007-08-10 | 2012-11-22 | Myriel Pharmaceuticals, Llc | DHEA compositions for treating menopause |
EA020683B1 (en) * | 2007-08-10 | 2015-01-30 | Эндорешерш, Инк. | Method for treating or reducing acquiring symptoms or diseases in postmenopausal women, intravaginal composition and suppository used therein |
US8957054B2 (en) | 2007-08-10 | 2015-02-17 | Endorecherche, Inc. | Pharmaceutical compositions |
US10881650B2 (en) | 2007-08-10 | 2021-01-05 | Endorecherche, Inc. | Pharmaceutical compositions |
US8629129B2 (en) | 2007-08-10 | 2014-01-14 | Endorecherche, Inc. | Pharmaceutical compositions |
WO2009021323A1 (en) * | 2007-08-10 | 2009-02-19 | Endorecherche, Inc. | Dhea compositions for treating menopause |
WO2011156908A1 (en) * | 2010-06-16 | 2011-12-22 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
EA026675B1 (en) * | 2010-06-16 | 2017-05-31 | Эндорешерш, Инк. | Methods of treating or preventing estrogen-dependent diseases |
US11576891B2 (en) | 2010-06-16 | 2023-02-14 | Endorecherche, Inc. | Methods of treating or preventing estrogen-related diseases |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US10548903B2 (en) | 2014-03-10 | 2020-02-04 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
WO2015135061A1 (en) * | 2014-03-10 | 2015-09-17 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with serm |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2334577A1 (en) | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | |
HUP0204211A2 (en) | Selective estrogen receptor modulators in combination with estrogens and pharmaceutical compositions containing them | |
CA2467222A1 (en) | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy | |
AU6958996A (en) | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis | |
MY125821A (en) | Pharmaceutical composition of topiramate | |
NO20024907L (en) | 8 <beta> -substituted-11 <beta> -pentyl and 11 <beta> -hexyl-eastern-1,3,5 (10) triene derivatives | |
IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
HUP0101693A3 (en) | Use of steroidal sapogenins and their derivatives for producing pharmaceutical compositions for the treatment of alzheimeirs disease | |
WO2001003687A3 (en) | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans | |
PT956024E (en) | MONOPHASIC ORAL CONTRACEPTIVE METHOD AND COVER ("KIT") COMPREHENDING A COMBINATION OF A PROGESTINE AND ESTROGEN | |
HUP0102913A3 (en) | Use of biogenic estrogen sulfamates for producing pharmaceutical compositions for hormone replacement therapy | |
CA2258177A1 (en) | 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function | |
PT921804E (en) | BIPHASIC AND JOINT CONTRACEPTIVE METHOD ("KIT") COMPREHENDING A COMBINATION OF A PROGESTINE AND A STRTRENGTH | |
WO1999045886A3 (en) | New contraceptive kit for monotherapy | |
CA2395481A1 (en) | Hormone receptor modulation | |
HUP0202429A2 (en) | Use of mesoprogestins (progesterone receptor modulators) for the preparation of pharmaceutical compositions for the treatment and prevention of benign hormone dependent gynecological disorders | |
CA2382106A1 (en) | Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds | |
SI20851B (en) | Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt) | |
WO2000067708A3 (en) | Oral steroidal hormone compositions and methods of use | |
BR0016737A (en) | 14,15-cyclopropane-unsaturated androstanes, processes for their preparation and pharmaceutical compositions containing these compounds | |
BR0116127A (en) | Compound, pharmaceutical composition, use of a compound, and, male contraceptive kit | |
ATE218366T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING FACTOR XIIIA FOR NERVE HEALING |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20190610 |